Latest News
Sanofi reports positive phase 3 results for Nexviazyme in infantile-onset Pompe disease
30 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that its Phase 3 Baby-COMET study met its primary endpoint, with treatment-naïve infants aged six months and younger with infantile-onset...
Zelluna awarded NOK16m research grant for Phase 1 cancer study
30 June 2026 - Zelluna ASA (OSE:ZLNA), a Norway-based company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer, said on Tuesday that it has been awarded a NOK16m grant by ...
AMR Clinical acquires ClinOhio Research Services
30 June 2026 - AMR Clinical, a US-based, multi-site research company, said on Monday it has acquired ClinOhio Research Services (ClinOhio), a multi-therapeutic research site founded in 2017 and based in Columbus, Ohio.AMR says that the acquisition ex...
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
30 June 2026 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based biotechnology company involved in the treatment and prevention of cancer, announced on Monday that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number ...
Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK
30 June 2026 - Nuvation Bio (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has validated the Mark...